首页> 美国卫生研究院文献>Infectious Disease Reports >Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development
【2h】

Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development

机译:将可持续利用政策与新颖的经济激励机制挂钩以刺激抗生素的研发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is now global recognition that antibiotic resistance is an emerging public health threat. Policy initiatives are underway to provide concrete suggestions for overcoming important obstacles in the fight against antibiotic resistance, like the alarming current paucity of antibacterial innovation. New economic models are needed as incentives for the discovery and development of novel antibacterial therapies especially for infections with too few patients today to justify private sector research and development (R&D) investments. These economic models should focus on rewarding the innovation, not the consumption of the antibiotic since sustainable use policies will reduce selection pressure and slow the emergence of resistance. To effectively stimulate greater innovation, the size of the reward must be commensurate with revenues from other therapeutic areas, estimated at about a billion dollar total pay-out. Otherwise R&D investment will continue to move away from antibiotics to areas where returns are more attractive. A potential sizeable public investment, if implemented, must be protected to ensure that the resulting antibiotics have a lengthy and positive impact on human health. Therefore, public investments in innovation should be bound to sustainable use policies, i.e., policies targeted at a range of actors to ensure the preservation of the novel antibiotics. These policies would be targeted not only at the innovating pharmaceutical companies in exchange for the reward payments, but also at governments in countries which receive the novel antibiotics at reasonable prices due to the reward payment. This article provides some suggestions of sustainable use policies in order to initiate the discussions. These are built on planned policies in the US, EU, WHO and have been expanded to address One Health and environmental aspects to form One World approaches. While further discussion and analyses are needed, it is likely that strong sustainable use policies will help to protect the sizeable public health investments.
机译:现在,全球公认抗生素抗性是正在出现的公共卫生威胁。目前正在采取政策举措,以提供具体建议,以克服抗药性耐药性方面的重要障碍,例如目前令人担忧的缺乏抗菌创新。需要新的经济模式来激励人们发现和开发新的抗菌疗法,尤其是对于如今患者人数太少而无法证明私营部门研发投入的感染。这些经济模式应侧重于奖励创新,而不是抗生素的消费,因为可持续利用政策将减少选择压力并减缓耐药性的出现。为了有效地刺激更大的创新,奖励的规模必须与其他治疗领域的收入相称,估计总支出约为10亿美元。否则,研发投资将继续从抗生素转移到回报更具吸引力的领域。如果实施了一项潜在的大规模公共投资,则必须加以保护,以确保所产生的抗生素对人类健康产生长期而积极的影响。因此,对创新的公共投资应受可持续利用政策的约束,即针对一系列行为者的政策,以确保新型抗生素的保存。这些政策不仅针对创新的制药公司以换取奖励金,而且还针对因奖励金而以合理价格获得新型抗生素的国家的政府。本文提供了一些有关可持续利用政策的建议,以启动讨论。这些是在美国,欧盟,世界卫生组织的计划政策基础上建立的,并已扩展到解决“一个健康”和环境方面,以形成“一个世界”方法。尽管有必要进行进一步的讨论和分析,但强有力的可持续利用政策可能会有助于保护大量的公共卫生投资。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号